Q2 FY2026 EarningsQ2 FY26 beat consensus significantly across all key top and bottom-line metrics: revenue of $256.1M vs. $221.1M expected, and diluted GAAP EPS of $0.36 vs. $0.02 expected. The beat was driven by the rapid uptake of Lifyorli ($47.6M in its first full quarter) and continued record prescriptions for Korlym. Management raised FY26 revenue guidance to $1.1B – $1.2B, well above previous expectations, reflecting strong AI-like momentum in the oncology and Cushing’s segments.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Corcept Therap(CORT) the Revenue is 256.15 M (+31.74%), Beat estimate;the EBIT is 41.3 M (+54.83%), Beat estimate;the EPS is 0.36 (+24.14%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.26B31.74%
0.22B13.74%
+0.04B18.00%
EBITExceed expectations
0.04B54.83%
-0.00B108.54%
+0.04B163.37%
EPSExceed expectations
0.3624.14%
0.0293.10%
+0.3400117.24%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf